LSE:AZNPharmaceuticals
AstraZeneca FDA Wins Expand Cardiovascular And Oncology Growth Potential
AstraZeneca received US FDA approval for Baxfendy, a first in class treatment for resistant hypertension, expanding its cardiovascular portfolio.
The US FDA also approved Enhertu for new early breast cancer settings, widening its use in HER2 positive disease.
These decisions extend AstraZeneca's reach into large, underserved patient groups across cardiovascular and oncology segments.
AstraZeneca (LSE:AZN), recently trading around £139.5, has seen strong longer term share performance, with...